New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia
Evaluation of New Markers for Minimal Residual Disease in Precursor B Acute Lymphoblastic Leukemia
1 other identifier
observational
50
1 country
1
Brief Summary
Acute lymphoblastic leukemia , also known as acute lymphocytic leukemia, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts, causing damage and death by inhibiting the production of normal cells (such as red and white blood cells and platelets) in the bone marrow and by spreading (infiltrating) to other organs. Acute lymphoblastic leukemia is most common in childhood, with a peak incidence at 2-5 years of age and another peak in old age.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2017
CompletedFirst Posted
Study publicly available on registry
August 15, 2017
CompletedStudy Start
First participant enrolled
December 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2019
CompletedAugust 29, 2017
August 1, 2017
1.3 years
August 9, 2017
August 28, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Level of expression of markers in acute lymphoblastic leukemia.
Level of expression of CD66c, CD 123 \& CD 73 in acute lymphocytic leukemia ,the correlation with each other .and with the clinical assessment of patients before and after induction
1 year
Study Arms (1)
ALL patients
New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
Interventions
Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
Eligibility Criteria
New cases of patients with acute lymphocytic leukemia.
You may qualify if:
- \. New cases of patients with acute lymphocytic leukemia. 2. Evaluation of markers 15 days after induction.
You may not qualify if:
- Patients died after induction
- Patients diagnosed as Non Hodgkin Lymphoma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut University
Asyut, Egypt
Related Publications (3)
Campana D, Coustan-Smith E. Measurements of treatment response in childhood acute leukemia. Korean J Hematol. 2012 Dec;47(4):245-54. doi: 10.5045/kjh.2012.47.4.245. Epub 2012 Dec 24.
PMID: 23320002BACKGROUNDCampana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000 Sep 21;243(1-2):59-75. doi: 10.1016/s0022-1759(00)00228-3.
PMID: 10986407BACKGROUNDInaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013 Jun 1;381(9881):1943-55. doi: 10.1016/S0140-6736(12)62187-4. Epub 2013 Mar 22.
PMID: 23523389BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Maureen R Farag, Resident
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 15 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 9, 2017
First Posted
August 15, 2017
Study Start
December 1, 2017
Primary Completion
April 1, 2019
Study Completion
October 1, 2019
Last Updated
August 29, 2017
Record last verified: 2017-08